{"id":753549,"date":"2025-07-24T16:24:01","date_gmt":"2025-07-24T16:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=753549"},"modified":"2025-07-24T16:24:01","modified_gmt":"2025-07-24T16:24:01","slug":"myopic-macular-degeneration-market-to-reach-usd-837-million-by-2034-driven-by-high-myopia-prevalence-and-antivegf-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myopic-macular-degeneration-market-to-reach-usd-837-million-by-2034-driven-by-high-myopia-prevalence-and-antivegf-therapies-delveinsight_753549.html","title":{"rendered":"Myopic Macular Degeneration Market to Reach USD 837 Million by 2034, Driven by High Myopia Prevalence and Anti-VEGF Therapies | DelveInsight"},"content":{"rendered":"
\n
\"Myopic<\/a><\/div>\n
\n
Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast \u2013 2034<\/div>\n<\/div>\n<\/div>\n
The myopic macular degeneration market is experiencing steady expansion, driven by increasing prevalence of high myopia, growing awareness of vision-threatening complications, and targeted therapies from key pharmaceutical players, including Roche, Bayer, Regeneron Pharmaceuticals, and others, advancing innovative solutions to address unmet needs and improve patient outcomes worldwide.<\/div>\n

DelveInsight’s “Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast – 2034<\/a><\/strong>” report delivers an in-depth understanding of the myopic macular degeneration treatment landscape, historical and forecasted epi across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates current treatment practices, emerging therapies, market share of individual treatments, and myopic macular degeneration market forecasts through 2034, providing crucial insights for stakeholders in the ophthalmology therapeutic area.<\/p>\n

According to DelveInsight’s analysis, the myopic macular degeneration market is projected to grow from approximately USD 734 million in 2022 to nearly USD 837 million by 2034<\/strong>, representing steady growth throughout the forecast period despite a scarcity of emerging therapies. The market growth is primarily driven by the increasing prevalence of high myopia and associated complications, with anti-VEGF therapies and standard of care forming the backbone of current treatment approaches.<\/p>\n

Download the Myopic Macular Degeneration Market report<\/a> to understand market dynamics and treatment landscape trends.<\/em><\/p>\n

According to DelveInsight’s estimates, the total diagnosed prevalent cases of myopic macular degeneration in the 7MM were approximately 4.1 million in 2022<\/strong> and are projected to increase during the forecast period. Japan accounts for the highest prevalence of diagnosed myopic macular degeneration cases, comprising 49% of the total cases<\/strong> in the 7MM in 2022. The United States contributes approximately 27% of the diagnosed cases, with about 1.1 million cases, while among EU4 and the UK, France had the highest diagnosed prevalent population, with about 0.27 million cases.<\/p>\n

DelveInsight’s analysis reveals that females are predominantly more affected<\/strong> by myopic macular degeneration in the 7MM, with this gender discrepancy potentially influenced by various factors, including hormonal, genetic, or environmental considerations. Choroidal neovascularization (CNV), a concerning complication of myopia or pathological myopia, represents a critical segment with diagnosed prevalent cases of mCNV accounting for 5% of the total myopic macular degeneration cases in the 7MM in 2022.<\/p>\n

Discover evolving trends in the Myopic Macular Degeneration patient pool forecasts @ Myopic Macular Degeneration Epidemiology Analysis<\/a>.<\/em><\/p>\n

Currently, there is no available treatment<\/strong> for myopic maculopathy except for mCNV, creating a pressing need for more treatment options. Present treatments for myopic macular degeneration align with wet AMD approaches, utilizing anti-VEGF medications. LUCENTIS (ranibizumab), the first FDA-approved anti-VEGF therapy for treating mCNV, was approved in January 2017, though the availability of biosimilars may impact its market dynamics due to patent expiration.<\/p>\n

EYLEA (aflibercept) by Bayer\/Regeneron Pharmaceuticals<\/strong> dominates as a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. EYLEA, the sole approved mCNV treatment in Japan and Europe with an active patent, maintains market significance unaffected by biosimilar competition. The drug helps prevent VEGF-A and PLGF from interacting with their natural VEGF receptors while ensuring a commendable safety profile.<\/p>\n

According to the DelveInsight report, the myopic macular degeneration therapies pipeline is currently limited, with VABYSMO (faricimab) representing a promising development<\/strong>. VABYSMO is the first bispecific antibody designed for the eye, targeting and inhibiting two signaling pathways linked to vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and VEGF-A. The absence of approved alternatives for mCNV treatment highlights the significant potential for VABYSMO to contribute substantially to the expansion of the myopic macular degeneration treatment market. While faricimab is not specifically in Roche’s pipeline for mCNV treatment, a Phase III trial is registered, with potential launch anticipated by 2028, with medium uptake expected in the US.<\/p>\n

Dive Deeper into the evolving treatment landscape @ Myopic Macular Degeneration Emerging Therapies.<\/a><\/em><\/p>\n

Recent developments in the treatment landscape highlights the evolving landscape. In 2024, the FDA approved several biosimilars to Eylea (aflibercept), including YESAFILI, OPUVIZ, AHZANTIVE, ENZEEVU, and PAVBLU<\/strong>. This increases affordability and access to anti-VEGF therapy, a crucial treatment for mCNV and other retinal conditions.<\/p>\n

ENCELTO was approved by the FDA in March 2025<\/strong>. While not directly for myopic maculopathy, this approval is significant as ENCELTO is a gene therapy implant<\/strong> that aims to slow the loss of macular photoreceptors. This opens the door for potential future gene therapies targeting macular degeneration in myopic patients.<\/p>\n

Discover recent advancements in the Myopic Macular Degeneration treatment landscape @ Myopic Macular Degeneration Recent Developments<\/a>.<\/em><\/p>\n

The market is characterized by established players, including Roche, Bayer, and Regeneron Pharmaceuticals, who continue to advance innovative therapies through robust research and development initiatives. These companies are focusing on addressing the significant unmet medical needs in myopic macular degeneration treatment, particularly for conditions beyond mCNV.<\/p>\n

Looking ahead, the myopic macular degeneration market faces both challenges and opportunities. While the current pipeline remains limited, increased awareness and extensive research indicate a gradual market expansion. The projected introduction of VABYSMO for mCNV treatment is anticipated to propel the overall market growth, promising a future characterized by more effective management protocols for this vision-threatening condition.<\/p>\n

DelveInsight’s analysis underscores the substantial opportunities for developing comprehensive therapeutic approaches that can address the broader spectrum of myopic macular degeneration beyond mCNV. As research continues and clinical understanding advances, the myopic macular degeneration market is positioned for measured but meaningful growth through 2034, with the potential for breakthrough therapies to transform patient outcomes in this challenging ophthalmic condition.<\/p>\n

Table of Contents<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary of Myopic Macular Degeneration<\/p>\n

3. Competitive Intelligence Analysis for Myopic Macular Degeneration<\/p>\n

4. Myopic Macular Degeneration Market Overview at a Glance<\/p>\n

5. Myopic Macular Degeneration: Disease Background and Overview<\/p>\n

6. Myopic Macular Degeneration Patient Journey<\/p>\n

7. Myopic Macular Degeneration Epidemiology and Patient Population<\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Myopic Macular Degeneration Unmet Needs<\/p>\n

10. Key Endpoints of Myopic Macular Degeneration Treatment<\/p>\n

11. Myopic Macular Degeneration Marketed Products<\/p>\n

12. Myopic Macular Degeneration Emerging Therapies<\/p>\n

13. Myopic Macular Degeneration: Seven Major Market Analysis<\/p>\n

14. Attribute analysis<\/p>\n

15. 7MM: Market Outlook<\/p>\n

16. Access and Reimbursement Overview of Myopic Macular Degeneration<\/p>\n

17. KOL Views<\/p>\n

18. Myopic Macular Degeneration Market Drivers<\/p>\n

19. Myopic Macular Degeneration Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

23. About DelveInsight<\/p>\n

About DelveInsight<\/strong><\/p>\n

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Arpit Anand
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +14699457679
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast \u2013 2034 The myopic macular degeneration market is experiencing steady expansion, driven by increasing prevalence of high myopia, growing awareness of vision-threatening complications, and targeted therapies from key pharmaceutical players, including … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-753549","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/753549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=753549"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/753549\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=753549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=753549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=753549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}